{"id":"cisplatin-for-injection","safety":{"commonSideEffects":[{"rate":"28-36%","effect":"Nephrotoxicity"},{"rate":"25-30%","effect":"Ototoxicity"},{"rate":"76-99%","effect":"Nausea and vomiting"},{"rate":"25-30%","effect":"Myelosuppression"},{"rate":"18-35%","effect":"Peripheral neuropathy"},{"rate":"29-47%","effect":"Electrolyte abnormalities (hypomagnesemia, hypokalemia)"},{"rate":"20-25%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which distort the DNA helix and block DNA synthesis and transcription. This leads to apoptosis and cell death in rapidly dividing cancer cells. The drug is non-cell-cycle specific and acts as an alkylating agent.","oneSentence":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:04.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic testicular cancer"},{"name":"Metastatic ovarian cancer"},{"name":"Advanced bladder cancer"},{"name":"Head and neck cancer"},{"name":"Lung cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":"Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC","enrollment":30},{"nctId":"NCT04910386","phase":"PHASE2","title":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2027-06-01","conditions":"Biliary Tract Neoplasms","enrollment":126},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT02997332","phase":"PHASE1","title":"Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-03-30","conditions":"Head and Neck Cancers","enrollment":14},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07125755","phase":"PHASE3","title":"Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-15","conditions":"Squamous Cell Cancer of Head and Neck (SCCHN)","enrollment":386},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT06157827","phase":"PHASE1, PHASE2","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2023-12-08","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT07111546","phase":"PHASE2","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-10-20","conditions":"Advanced Solid Tumour","enrollment":140},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT04030455","phase":"PHASE2","title":"Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-07","conditions":"Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8","enrollment":28},{"nctId":"NCT07331155","phase":"PHASE2","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-02-26","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT07449949","phase":"","title":"A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma","status":"ENROLLING_BY_INVITATION","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-10-30","conditions":"ORR, PFS, OS","enrollment":43},{"nctId":"NCT07447570","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-15","conditions":"Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody","enrollment":27},{"nctId":"NCT07445048","phase":"PHASE3","title":"Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2026-03-05","conditions":"Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, Postoperative Adjuvant Treatment","enrollment":370},{"nctId":"NCT07310784","phase":"PHASE2","title":"A Phase II Trial of LM103 in Advanced Melanoma","status":"RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2025-12-16","conditions":"Advanced Melanoma","enrollment":92},{"nctId":"NCT07446335","phase":"PHASE3","title":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-04","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":578},{"nctId":"NCT06772623","phase":"PHASE1, PHASE2","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-03-06","conditions":"Non Small Cell Lung Carcinoma","enrollment":252},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT05544136","phase":"PHASE2","title":"A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-12","conditions":"Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms","enrollment":12},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer","enrollment":673},{"nctId":"NCT07430579","phase":"NA","title":"Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The Second Hospital of Shandong University","startDate":"2024-12-09","conditions":"Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events","enrollment":25},{"nctId":"NCT04620187","phase":"PHASE2","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-24","conditions":"Salivary Gland Cancer, HER2 Gene Mutation","enrollment":55},{"nctId":"NCT06236438","phase":"PHASE2, PHASE3","title":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-04-10","conditions":"Non-Small Cell Lung Cancer","enrollment":840},{"nctId":"NCT05403723","phase":"PHASE1","title":"Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","status":"SUSPENDED","sponsor":"University of Maryland, Baltimore","startDate":"2026-06-30","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT06059261","phase":"PHASE2","title":"Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2026-02-09","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT07407452","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-01","conditions":"Ovarian Cancers","enrollment":50},{"nctId":"NCT06956001","phase":"PHASE3","title":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-11-19","conditions":"EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":300},{"nctId":"NCT06970639","phase":"PHASE3","title":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-09-26","conditions":"NSCLC Patients With Brain Metastasis","enrollment":380},{"nctId":"NCT06557889","phase":"PHASE2","title":"Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2024-10-21","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":86},{"nctId":"NCT07326137","phase":"","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-26","conditions":"Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain","enrollment":103},{"nctId":"NCT04585477","phase":"PHASE2","title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-04-08","conditions":"Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II","enrollment":80},{"nctId":"NCT07398339","phase":"PHASE2","title":"Cosiporfin Sodium for Injection Photodynamic Therapy","status":"RECRUITING","sponsor":"Shanghai Guangsheng Biopharmaceutical Co., Ltd","startDate":"2026-03-31","conditions":"Biliary Tract Cancers (BTC)","enrollment":30},{"nctId":"NCT07392580","phase":"PHASE2","title":"Intralesional Chemotherapy (IC): Cisplatin + Epinephrine","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04-01","conditions":"Laryngeal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT02662504","phase":"PHASE2","title":"Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2016-01-16","conditions":"Malignant Pleural Mesothelioma","enrollment":6},{"nctId":"NCT07383116","phase":"PHASE3","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2026-01-15","conditions":"Non Squamous Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT07381829","phase":"PHASE1","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-10-27","conditions":"Advanced Solid Tumor Cancer","enrollment":328},{"nctId":"NCT04161248","phase":"EARLY_PHASE1","title":"Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2020-09-02","conditions":"Lymphoma, B-Cell","enrollment":18},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07376499","phase":"PHASE2","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-01-25","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT07372079","phase":"PHASE2","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-05","conditions":"Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":40},{"nctId":"NCT07229625","phase":"PHASE3","title":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-01-21","conditions":"Advanced Biliary Tract Cancer","enrollment":604},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT07351565","phase":"PHASE1","title":"Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2026-01-10","conditions":"Non-Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT07349225","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Dalian Medical University","startDate":"2026-01-31","conditions":"ES-SCLC","enrollment":46},{"nctId":"NCT05522985","phase":"PHASE2","title":"Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-11-07","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy","enrollment":122},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT06703398","phase":"PHASE2","title":"A Study of GC101 TIL in Advanced Melanoma","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2024-12-20","conditions":"Melanoma","enrollment":98},{"nctId":"NCT06512051","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-07-30","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":248},{"nctId":"NCT07295262","phase":"EARLY_PHASE1","title":"NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-01","conditions":"Liver Cancer, Adult","enrollment":30},{"nctId":"NCT07291063","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-07-19","conditions":"Cholangiocarcinoma","enrollment":50},{"nctId":"NCT07290010","phase":"PHASE2","title":"The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":25},{"nctId":"NCT06866951","phase":"PHASE2, PHASE3","title":"A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial","status":"WITHDRAWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-01","conditions":"Cervical Cancers","enrollment":""},{"nctId":"NCT07281508","phase":"PHASE3","title":"Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-08-14","conditions":"Cisplatin-related Hearing Loss","enrollment":100},{"nctId":"NCT06783140","phase":"PHASE2, PHASE3","title":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-06-10","conditions":"Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation","enrollment":10},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT05516914","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2022-09-01","conditions":"Malignant Tumors","enrollment":490},{"nctId":"NCT07241767","phase":"PHASE2","title":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-11-12","conditions":"Lung Cancer","enrollment":200},{"nctId":"NCT07168200","phase":"PHASE3","title":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-10-17","conditions":"Advanced Cervical Cancer","enrollment":720},{"nctId":"NCT06927986","phase":"PHASE3","title":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","status":"RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-30","conditions":"EGFR-mutated Locally Advanced or Metastatic NSCLC","enrollment":380},{"nctId":"NCT03582475","phase":"PHASE1","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-11","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":15},{"nctId":"NCT06212752","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-13","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":39},{"nctId":"NCT05541016","phase":"PHASE2","title":"De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-02-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":455},{"nctId":"NCT04311762","phase":"PHASE1","title":"Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Vermont","startDate":"2020-02-01","conditions":"Lung Cancer Metastatic","enrollment":16},{"nctId":"NCT01495676","phase":"NA","title":"A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer","status":"TERMINATED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2011-07-06","conditions":"Infiltrating Bladder Urothelial Carcinoma","enrollment":69},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT03127774","phase":"PHASE2","title":"Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma","status":"RECRUITING","sponsor":"Columbia University","startDate":"2017-09-22","conditions":"Adrenocortical Carcinoma, Peritoneal Carcinomatosis","enrollment":30},{"nctId":"NCT04325425","phase":"PHASE2","title":"Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-09-01","conditions":"Neuroendocrine Carcinoma","enrollment":218},{"nctId":"NCT07188441","phase":"PHASE2","title":"Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.","status":"RECRUITING","sponsor":"Chengcheng Guo","startDate":"2024-08-13","conditions":"GCT, Germ Cell Tumor, Central Malignant Germ Cell Tumor","enrollment":40},{"nctId":"NCT06385678","phase":"PHASE1, PHASE2","title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-07-05","conditions":"Advanced KRAS G12D Mutant Solid Tumors","enrollment":47},{"nctId":"NCT03298893","phase":"PHASE1, PHASE2","title":"Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2017-11-27","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer","enrollment":21},{"nctId":"NCT05570422","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01","status":"NOT_YET_RECRUITING","sponsor":"Kortuc, Inc.","startDate":"2025-12-01","conditions":"Cervical Cancer","enrollment":70},{"nctId":"NCT05722015","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-14","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":377},{"nctId":"NCT04369937","phase":"PHASE2","title":"HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for \"Intermediate Risk\" HPV-16-associated Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-07-06","conditions":"HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":18},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT07151872","phase":"PHASE2","title":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09","conditions":"CLDN18.2-positive Advanced Biliary Tract Cancer","enrollment":120},{"nctId":"NCT03581786","phase":"PHASE3","title":"The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2018-10-18","conditions":"Recurrent or Metastatic NPC","enrollment":289},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07138001","phase":"PHASE2","title":"Phase 2 Clinical Trial of KH617","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","startDate":"2025-08","conditions":"Recurrent Glioblastoma","enrollment":60},{"nctId":"NCT07131345","phase":"PHASE1, PHASE2","title":"Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center, China","startDate":"2025-09-01","conditions":"Malignant Mesothelioma, Mesothelioma","enrollment":55},{"nctId":"NCT06492460","phase":"PHASE3","title":"2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-20","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":422},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":"Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8","enrollment":50},{"nctId":"NCT06356688","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Jing","startDate":"2025-04-20","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":30},{"nctId":"NCT05173246","phase":"PHASE2","title":"JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-11-17","conditions":"Esophageal Small Cell Carcinoma","enrollment":43},{"nctId":"NCT03502785","phase":"PHASE1, PHASE2","title":"INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-24","conditions":"Urothelial Carcinoma","enrollment":35},{"nctId":"NCT07054086","phase":"","title":"Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-03-01","conditions":"Esophageal Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cisplatin for injection","genericName":"Cisplatin for injection","companyName":"Shanghai Guangsheng Biopharmaceutical Co., Ltd","companyId":"shanghai-guangsheng-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin for injection is a small molecule used to treat various types of cancer, including breast cancer, bile duct carcinoma, gall bladder cancer, biliary tract cancer, and cholangiocarcinoma. It is typically administered as part of a combination therapy, such as with gemcitabine, and has been studied in clinical trials for its effectiveness in these conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}